β₂ long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD.
about
Long-acting beta 2 -agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary diseaseThe pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder diseaseCan the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?Formoterol is more effective than salmeterol in suppressing neutrophil reactivityThe long-acting β2 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation.New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol.Olodaterol: first global approval.Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease.Molecular pathogenesis of cigarette smoking-induced stable COPD.Bronchodilators, receptors and cross-talk: Together is better?Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.Tiotropium/Olodaterol: A Review in COPD.Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update.Chronic inflammatory airway diseases: the central role of the epithelium revisited.Bifunctional Drugs for the Treatment of Respiratory Diseases.How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?Pathological Roles of Neutrophil-Mediated Inflammation in Asthma and Its Potential for Therapy as a Target.Olodaterol + tiotropium bromide for the treatment of COPD.
P2860
Q24194044-38E77301-0A00-4ADB-9E4B-DFAF12BE5A0EQ26864937-D0757134-21C8-41F9-8A54-61B922D068C1Q28391808-7F2A1D9F-3468-4642-BBC6-693445710D01Q28596768-5BD678EE-73BA-47B6-A9B4-C56E3CC53DB3Q35865433-CD5CC15E-6B65-4ABB-83AE-5EC910AFFB99Q38154255-B35D5B25-CBC1-411E-AB9C-BE0F81D184D4Q38155451-45B3DAA5-3F9E-4E87-856E-141BEC37B650Q38241442-7610289A-89C5-4DF1-9414-D9FD948B02D1Q38339473-340F7411-B55C-4397-9AED-4A8AFA11A8C3Q38570698-702194A0-81DF-4A55-AC9E-046E20B9C225Q38570714-016AE642-00A3-4193-917C-97817C3A0FEBQ38673383-19D36C00-6E59-481C-99CA-02B399DAE2D9Q38754002-E88C1E0B-1322-48EF-B36B-6BBC4D6F6E46Q38791607-CC999BD7-20AF-4A10-80D5-3F22A49D2C2FQ38992596-949ED6ED-E828-4A18-8359-3FD8821D0567Q39030602-5A8EC383-E874-4790-8ABE-1022DC3494AAQ47650425-32FFDCD1-3F6F-4DE2-BA36-EA975F133921Q51545895-3BF8A057-C8AB-4116-9229-D1114BE19DCE
P2860
β₂ long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
β₂ long-acting and anticholine ...... rophilic inflammation in COPD.
@en
β₂ long-acting and anticholine ...... rophilic inflammation in COPD.
@nl
type
label
β₂ long-acting and anticholine ...... rophilic inflammation in COPD.
@en
β₂ long-acting and anticholine ...... rophilic inflammation in COPD.
@nl
prefLabel
β₂ long-acting and anticholine ...... rophilic inflammation in COPD.
@en
β₂ long-acting and anticholine ...... rophilic inflammation in COPD.
@nl
P2093
P50
P1476
β₂ long-acting and anticholine ...... rophilic inflammation in COPD.
@en
P2093
Angela Marina Montalbano
Giusy Daniela Albano
Maria Ferraro
Mark Gjomarkaj
Michael Paul Pieper
Paola Casarosa
P304
P356
10.1016/J.BBADIS.2012.03.002
P407
P577
2012-03-13T00:00:00Z